The Psychedelic-Informed Care & Referrals Primer for Practitioners
What psychedelic-informed care and referrals actually mean
Psychedelic-informed care does not require you to administer psychedelic medicines, endorse their use, or refer every curious patient down a treatment pathway. It means you can respond responsibly when the subject enters the room, because it will, whether or not you invited it in.
Here are the practical and legal considerations to know about psychedelic-informed care and referrals.
Midwives: 5 Strategies for Escalation, Co-management, and Referral
Let’s say my patient is in active labor, and I know this patient’s birth with her first baby included shoulder dystocia. Let’s say this patient has a high BMI, and the baby’s head is not descended in an expected manner, although she is fully dilated. In this hypothetical scenario, the timely call would include me calling the ob/gyn (or family physician) and saying, “I think I want you here in the second stage of labor, because the risk of shoulder dystocia might be elevated.”
This proactive approach promotes much better outcomes than waiting until the turtle sign to escalate.
By laying the groundwork for care escalation in advance, all practitioners and practices can promote patient safety while mitigating their own liability risks. The following are five key strategies.
Collecting Women's Health Data in Clinical Practice: A Guide for Clinicians, Clinic Owners, and Research Directors
Most clinics are sitting on valuable data; data that can inform how care is provided, what medication labels say, and what future clinical trials get funded to study!
5 Non-Negotiable Supplements During Pregnancy
As a dietitian, I am always preaching a food-first approach. But during pregnancy, our nutrient needs increase dramatically, making it challenging, and sometimes overwhelming, to meet every nutrient requirement through food alone.
How to talk to your patients about Ketamine Therapy
A 6-step framework for clinicians.
Raising the ketamine therapy conversation with a patient can feel challenging. This guide gives you the framework to start it, sustain it, and close it with a referral.
COMP360 REMS & Future Practice: What Clinics Need to Know
COMP360, Compass Pathways' investigational synthetic psilocybin, is one FDA approval away from becoming the first classic psychedelic cleared for the U.S. market. With positive results from two large Phase 3 trials in treatment-resistant depression (TRD) and a rolling New Drug Application (NDA) targeted for Q4 2026, the regulatory path is coming into sharp focus — and so is the likely structure of the FDA's Risk Evaluation and Mitigation Strategy (REMS).
The Women's Health Toolkit by GALILEA®
A women’s health toolkit that can be integrated into any practice!